Go to
current issue
-
Antibodies to combat viral infections: development strategies and progress Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-20 Giuseppe Pantaleo, Bruno Correia, Craig Fenwick, Victor S. Joo, Laurent Perez
-
From pandemic preparedness to public–private partnerships Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-17
Julie Gerberding — incoming CEO of the Foundation for the NIH (FNIH), and former Director of the CDC and executive at Merck & Co. — discusses COVID-19 learnings, centralized clinical trials and trust in science.
-
Upcoming market catalysts in Q3 2022 Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-16
Discover the world’s best science and medicine | Nature.com
-
What’s next for the synthetic lethality drug discovery engine? Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-16
As a surge of cancer drugs with new synthetic lethality targets enter the clinic, the opportunities and challenges of the underlying discovery strategies are coming into focus.
-
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-14 Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen
Tumours employ various tactics to adapt and eventually resist immune attack. These mechanisms are collectively called adaptive immune resistance (AIR). The first defined and therapeutically validated AIR mechanism is the selective induction of programmed cell death 1 ligand 1 (PDL1) by interferon-γ in the tumour. Blockade of PDL1 binding to its receptor PD1 by antibodies (anti-PD therapy) has resulted
-
Publisher Correction: Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-10 Fabien Vincent,Arsenio Nueda,Jonathan Lee,Monica Schenone,Marco Prunotto,Mark Mercola
-
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-09
Discover the world’s best science and medicine | Nature.com
-
BMS buys Turning Point Therapeutics and its kinase inhibitors for $4.1 billion Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-09
Discover the world’s best science and medicine | Nature.com
-
Novel antibiotics from bacterial blueprints Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-09
Discover the world’s best science and medicine | Nature.com
-
Vaccine exposes tumours to immune cell attack Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-09
Discover the world’s best science and medicine | Nature.com
-
A bacteria-derived oral tumour vaccine Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-08
Discover the world’s best science and medicine | Nature.com
-
Restoring memory in aged mice Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-08
Discover the world’s best science and medicine | Nature.com
-
Ketone body blocks intestinal tumour growth Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-08
Discover the world’s best science and medicine | Nature.com
-
Plant protein blocks tumour growth Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-08
Discover the world’s best science and medicine | Nature.com
-
Promoting efferocytosis heals diabetic wounds Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-07
Discover the world’s best science and medicine | Nature.com
-
Thinking outside the box: non-canonical targets in multiple sclerosis Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-06 Laura Bierhansl, Hans-Peter Hartung, Orhan Aktas, Tobias Ruck, Michael Roden, Sven G. Meuth
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that causes demyelination, axonal degeneration and astrogliosis, resulting in progressive neurological disability. Fuelled by an evolving understanding of MS immunopathogenesis, the range of available immunotherapies for clinical use has expanded over the past two decades. However, MS remains an incurable disease and
-
A nuclease inhibitor for neurodegeneration Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-01
Discover the world’s best science and medicine | Nature.com
-
Drugging the efferocytosis process: concepts and opportunities Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-01 Parul Mehrotra, Kodi S. Ravichandran
The daily removal of billions of apoptotic cells in the human body via the process of efferocytosis is essential for homeostasis. To allow for this continuous efferocytosis, rapid phenotypic changes occur in the phagocytes enabling them to engulf and digest the apoptotic cargo. In addition, efferocytosis is actively anti-inflammatory and promotes resolution. Owing to its ubiquitous nature and the sheer
-
Landscape of cancer cell therapies: trends and real-world data Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-06-01
Discover the world’s best science and medicine | Nature.com
-
Engineering the next generation of cell-based therapeutics Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-30 Caleb J. Bashor, Isaac B. Hilton, Hozefa Bandukwala, Devyn M. Smith, Omid Veiseh
Cell-based therapeutics are an emerging modality with the potential to treat many currently intractable diseases through uniquely powerful modes of action. Despite notable recent clinical and commercial successes, cell-based therapies continue to face numerous challenges that limit their widespread translation and commercialization, including identification of the appropriate cell source, generation
-
Phenotypic drug discovery: recent successes, lessons learned and new directions Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-30 Fabien Vincent, Arsenio Nueda, Jonathan Lee, Monica Schenone, Marco Prunotto, Mark Mercola
Many drugs, or their antecedents, were discovered through observation of their effects on normal or disease physiology. For the past generation, this phenotypic drug discovery approach has been largely supplanted by the powerful but reductionist approach of modulating specific molecular targets of interest. Nevertheless, modern phenotypic drug discovery, which combines the original concept with modern
-
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-20
Discover the world’s best science and medicine | Nature.com
-
Pfizer buys Biohaven’s migraine drugs for $11.6 billion Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-20
Discover the world’s best science and medicine | Nature.com
-
Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors? Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-17
Fouad Namouni, head of R&D at Blueprint Medicines, discusses how dual blockade of a single target could push the tyrosine kinase inhibitor envelope.
-
DNA damage response drugs for cancer yield continued synthetic lethality learnings Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-17
A PARP1-selective drug and a pipeline of ATR inhibitors demonstrate the near-term opportunities and long-term challenges for synthetic lethality in anticancer drug development.
-
Pfizer’s small-molecule antiviral misses on COVID prevention Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-10
Discover the world’s best science and medicine | Nature.com
-
FDA approves first cardiac myosin inhibitor Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-10
Discover the world’s best science and medicine | Nature.com
-
Pull incentives for antibiotics get push from the UK Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-10
Discover the world’s best science and medicine | Nature.com
-
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-10
Discover the world’s best science and medicine | Nature.com
-
Bispecific antibodies pin down cancer stem cells Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-10
Discover the world’s best science and medicine | Nature.com
-
Probing the antidepressant action of psychedelics Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-09
Discover the world’s best science and medicine | Nature.com
-
Understanding LAG3 effects on T cells Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-06
Discover the world’s best science and medicine | Nature.com
-
Targeted design of protein binders Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-06
Discover the world’s best science and medicine | Nature.com
-
Designing a novel synthetic receptor Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-06
Discover the world’s best science and medicine | Nature.com
-
Enhancing NK cell anti-tumour efficacy Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-06
Discover the world’s best science and medicine | Nature.com
-
Trends in innovative drug development in China Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-05
Discover the world’s best science and medicine | Nature.com
-
Imaging drug targets in the brain Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-05-04
Discover the world’s best science and medicine | Nature.com
-
The malignant melanoma market Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-27
Discover the world’s best science and medicine | Nature.com
-
Autotaxin inhibition to the rescue in stroke Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-26
Discover the world’s best science and medicine | Nature.com
-
opnMe.com: a digital initiative for sharing tools with the biomedical research community Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-22 Andreas Gollner, Markus Köster, Paul Nicklin, Thomas Trieselmann, Elliott Klein, Jaromir Vlach, Claudia Heine, Marc Grundl, Jürgen Ramharter, David Wyatt, Menorca Chaturvedi, Alessio Ciulli, Katharine C. Carter, Susanne Müller, Daniel Bischoff, Peter Ettmayer, Eric Haaksma, Jürgen Mack, Darryl McConnell, Dirk Stenkamp, Harald Weinstabl, Matthias Zentgraf, Clive R. Wood, Florian Montel
Pharmacological probes are important tools for exploring disease biology and discovering new therapies. Often molecules of insufficient quality are used instead, leading to spurious and misleading results. The Boehringer Ingelheim open innovation portal opnMe.com addresses this deficiency by sharing extensively validated pharmacological probes with the scientific community.
-
Electroceuticals jolt into the clinic, sparking autoimmune opportunities Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-19
As Galvani Bioelectronics advances its first ‘electroceutical’ candidate for a chronic disease into the clinic, company president Kristoffer Famm discusses the bioelectronic medicines R&D roadmap.
-
Pan-coronavirus vaccine pipeline takes form Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-19
Dozens of ‘universal’ coronavirus vaccines are in development. But will new technology platforms be able to overcome immunological unknowns?
-
T cell receptor therapeutics hit the immuno-oncology stage Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-19
With the FDA’s approval of the first TCR-based bispecific T cell engager, an emerging biological modality aims to take on new targets for solid cancers.
-
FDA new drug approvals in Q1 2022 Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-13
Discover the world’s best science and medicine | Nature.com
-
FDA approves first PSMA-targeted radiopharmaceutical Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-08
Discover the world’s best science and medicine | Nature.com
-
Roche’s anti-TIGIT drug suffers a phase III cancer setback Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-08
Discover the world’s best science and medicine | Nature.com
-
Vertex’s NaV1.8 inhibitor passes phase II pain point Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-08
Discover the world’s best science and medicine | Nature.com
-
Engineered IL-2 cytokine takes pivotal immuno-oncology blow Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-08
Discover the world’s best science and medicine | Nature.com
-
tRNA molecules run a STOP sign Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-08
Discover the world’s best science and medicine | Nature.com
-
Small-molecule screens for targeting non-coding RNA Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-07
Discover the world’s best science and medicine | Nature.com
-
Bacteria deliver the goods Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-07
Discover the world’s best science and medicine | Nature.com
-
Stapled peptide blocks mucus secretion Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-06 Sarah Crunkhorn
-
Targeting KRAS with reversible inhibitors Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-06 Sarah Crunkhorn
-
A spirulina-based biomanufacturing platform Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-06 Sarah Crunkhorn
-
Kinase drug discovery 20 years after imatinib Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-01
Following the landmark approval of imatinib 20 years ago, over 70 kinase inhibitors are now transforming the clinical care of multiple malignancies and a handful of other disorders.
-
Evolution of innovative drug R&D in China Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-04-01
Discover the world’s best science and medicine | Nature.com
-
Novel drug targets in 2021 Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-03-31
Discover the world’s best science and medicine | Nature.com
-
Antibody cocktail eliminates ebolaviruses Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-03-29
Discover the world’s best science and medicine | Nature.com
-
The emerging role of mass spectrometry-based proteomics in drug discovery Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-03-29 Felix Meissner, Jennifer Geddes-McAlister, Matthias Mann, Marcus Bantscheff
Proteins are the main targets of most drugs; however, system-wide methods to monitor protein activity and function are still underused in drug discovery. Novel biochemical approaches, in combination with recent developments in mass spectrometry-based proteomics instrumentation and data analysis pipelines, have now enabled the dissection of disease phenotypes and their modulation by bioactive molecules
-
Targeted protein degraders: a call for collective action to advance safety assessment Nat. Rev. Drug. Disc. (IF 84.694) Pub Date : 2022-03-23 Lyn H. Jones, Constance A. Mitchell, Lise Loberg, Mira Pavkovic, Mohan Rao, Ruth Roberts, Katie Stamp, Laurie Volak, Matthias B. Wittwer, Syril Pettit
Targeted protein degraders (TPDs) are emerging classes of therapeutics that have the potential to address difficult drug targets in new ways. In 2021, experts convened to discuss challenges in TPD safety evaluation, and supported supplementing individual efforts to address these challenges with collective development of novel decision frameworks, tools and a shared evidence base.
更新日期：2022-06-10
Copyright © 2014-2022 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号